Physician profile
Paul Maglione
NPI 1083856538
$65,834.71
in general payments reported to CMS, 2019-2025
8 companies · $44K in 2025
The $44K reported for 2025 was more than what 96% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.16 · 2020: $9,385 · 2021: $2,200 · 2022: $2,000 · 2023: $2,253 · 2024: $5,692 · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Honoraria: $4,300 · Travel and Lodging: $3,421 · Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,657.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,000.00 |
| Honoraria | $4,300.00 |
| Travel and Lodging | $3,420.54 |
| Food and Beverage | $803.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $36,595.14 | 2022-2025 | Joenja |
| Csl Behring | $9,685.34 | 2020-2024 | Hizentra |
| Novartis Pharmaceuticals Corporation | $8,349.03 | 2025 | |
| Adma Biomanufacturing LLC | $4,392.11 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,125.00 | 2021-2023 | |
| Genzyme Corporation | $2,292.00 | 2025 | |
| Horizon Therapeutics Plc | $396.09 | 2019-2023 | Actimmune |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Maglione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.